en · de · es · fr · pt
sr9009-notes.peptides6155.com › Blog › Analytical Detection And Storage — Explained

Analytical Detection And Storage — Explained

By Editorial Desk · published 2026-02-14 · last reviewed 2026-03-21 · Blog

Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-03-21. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Sr9009 at a glance

PropertyValueNotes
Typical storage temperature-20 °C or lowerDesiccated and protected from light
Common analytical methodLC-MS/MSDetects parent drug and metabolites
Solubility classLipophilic; soluble in organic solventsLow aqueous solubility
Molecular weight437.94 g/molCalculated from reported formula
SynonymsSR9009; REV-ERB agonistCode name used in scientific literature

Analytical Detection and Laboratory Handling

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Related pages on this site

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Supporting material

=== Box-office === The film opened on 6 November 1987 in limited release in 27 cinemas in eight U.S. markets. During its opening weekend, the film opened in 19th place and grossed $318,723. The film was originally set to expand on 20 November 1987, but it was delayed until February 1988. The film expanded to 479 screens for the weekend of 19–21 February and went on to gross $5,899,797 in the United States and Canada. The film was released in South Africa in July 1988 but was seized by police who claimed it was a threat to national security. It was approved for release the following month in several bantustans in South Africa. Internationally, the film grossed $46 million, for a worldwide total of $52 million. It earned £3,313,150 in the UK.

The three substrates of this enzyme are (R)-β-alanopine, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are β-alanine, reduced NADH, pyruvic acid and a proton. β-alanopine is a type of opine. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is N-(D-1-carboxyethyl)-beta-alanine:NAD+ oxidoreductase (beta-alanine-forming).

False positive readings can be due to various causes: liver disease, high rheumatoid factor, inflammation, malignancy, trauma, pregnancy, recent surgery as well as advanced age. False negative readings can occur if the sample is taken either too early after thrombus formation or if testing is delayed for several days. Additionally, the presence of anti-coagulation can render the test negative because it prevents thrombus extension. The anti-coagulation medications dabigatran and rivaroxaban decrease D-dimer levels but do not interfere with the D-dimer assay. False values may be obtained if the specimen collection tube is not sufficiently filled (false low value if underfilled and false high value if overfilled). This is due to the dilutional effect of the anticoagulant (the blood must be collected in a 9:1 blood to anticoagulant ratio). Likelihood ratios are derived from sensitivity and specificity to adjust pretest probability. Elevated plasma D-dimer levels following ICH serve as an independent risk factor for poor functional outcomes and mortality. In interpretation of the D-dimer, a value above 500 μg/L is considered abnormal. Since 2001 there have been numerous studies that show for patients over age 50, a value of (patient's age) × 10 μg/L may be abnormal; this has been validated in multiple different D-dimer assays. This has now been incorporated in clinical practice guidelines.

== Medical uses == The primary target for the development of FIAU was the treatment of chronic hepatitis B virus (HBV) infection. FIAU is a nucleoside analogue, meaning that the molecule is similar to the building blocks of deoxyribonucleic acid, DNA. Once it enters the body and it is phosphorylated by viral thymidine kinase the FIAU is activated. The FIAU will then be incorporated into the viral DNA while the virus is dividing. The virus will begin building a new DNA strand and use FIAU as a ‘building block’, but as it is an analogue and not a real nucleotide the DNA chain cannot be completed. FIAU was a potent inhibitor of HBV replication, thus resulting in a large decrease in serum HBV DNA levels. FIAU (and its parent drug FIAC) was also studied for the use in treating herpes simplex virus (HSV), varicella zoster virus (VZV), and cytomegalovirus (CMV). Nowadays FIAU is an important compound in the field of drug-induced liver injury research. FIAU, despite its early promise, was never put on the market and has never been available for medicinal use. In the initial clinical trials FIAU was a potent inhibitor of the HBV replication, as patients experienced a large decrease in serum HBV DNA levels. And in the high-dosed groups the HBV DNA was reduced by 70 to 95%. But even though the treatment was very promising, the antiviral effect was almost always temporary.

Meitnerium is a synthetic chemical element; it has symbol Mt and atomic number 109. It is an extremely radioactive synthetic element (not naturally occurring, but can be created in a laboratory). The most stable known isotope, meitnerium-278, has a half-life of 4.5 seconds, although the unconfirmed meitnerium-282 may have a longer half-life of 67 seconds. The element was first synthesized in August 1982 by the GSI Helmholtz Centre for Heavy Ion Research near Darmstadt, Germany, and it was named after the Austrian-Swedish nuclear physicist Lise Meitner in 1997. In the periodic table, meitnerium is a d-block transactinide element. It is a member of the 7th period and is placed in the group 9 elements, although no chemical experiments have yet been carried out to confirm that it behaves as the heavier homologue to iridium in group 9 as the seventh member of the 6d series of transition metals. Meitnerium is calculated to have properties similar to its lighter homologues, cobalt, rhodium, and iridium.

Sources: en.wikipedia.org

Supporting material

GLP1 poly-agonist peptides are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor. These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease. Unlike GLP-1 mono-agonists, which target only the GLP-1 receptor, poly-agonists activate two or more incretin receptors, such as the gastric inhibitory polypeptide (GIP) receptor, which have distinct features but work together in metabolic regulation. GIP and GLP-1 are both naturally released from the gastrointestinal tract after eating, but act on different receptor distributions across tissues. GLP-1 receptors are concentrated in the pancreas, brain, and gastrointestinal tract, while GIP receptors are found primarily in the pancreas, brain, and adipose tissue. In healthy people, the combined incretin effect of GIP and GLP-1 accounts for around 50–70% of post-meal insulin secretion. This effect is substantially reduced in people with type 2 diabetes, providing evidence for therapies that activate both hormones. Poly-agonists are expected to provide superior efficacy with fewer adverse effects compared to GLP-1 mono-agonists, which are dose-limited by gastrointestinal disturbances. The effectiveness of multi-receptor agonists could possibly equal or exceed that of bariatric surgery. The first such drug to receive approval is tirzepatide, a dual agonist of GLP-1 and GIP receptors.

The public's lack of understanding regarding nicotine's biological effects frequently results in inaccurate claims disseminated by the media and general public. In some anti-smoking literature, the harm that tobacco smoking and nicotine addiction does is personified as Nick O'Teen, represented as a humanoid with some aspect of a cigarette or cigarette butt about him or his clothes and hat. Nick O'Teen was a villain that was created for the Health Education Council. The character was featured in three animated anti-smoking public service announcements in which he tries to get kids addicted to cigarettes before being foiled by the DC Comics character Superman. Nicotine was often compared to caffeine in advertisements in the 1980s by the tobacco industry, and later in the 2010s by the electronic cigarettes industry, in an effort to reduce the stigmatization and the public perception of the risks associated with nicotine use.

Film laboratories or darkrooms Clandestine labs for the production of illegal drugs Computer labs Crime labs used to process crime scene evidence Language labs Medical labs (involves handling of chemical compounds) Public health labs Cleanrooms

"Cheese" is a heroin-based recreational drug that came to the attention of the media inside and outside the United States after a string of deaths among adolescents in Dallas, between 2005 and 2007. As of 2012 the drug use was now among older people who were teenagers around the period the drug was first discovered. Cheese is a combination of drugs, made by combining heroin with crushed tablets of certain over-the-counter cold medication, such as Tylenol PM. Such cold medications contain acetaminophen (paracetamol), the active ingredient in Tylenol, and the antihistamine diphenhydramine, the active ingredient in Benadryl. Cheese samples obtained in north Dallas contained between 2% and 8% heroin, in contrast to the 30% commonly found in black tar heroin. Users commonly take the powder by insufflation ("snorting") rather than by intravenous injection. This mixture is also known as "Tylenol With Smack", by analogy to the Tylenol With Codeine series. Due to the high concentrations of non-opiate substances relative to the diamorphine content of the drug, abuse and overdose of cheese are more dangerous than pure-form opiate overdoses. Emergency personnel must address the overdose effects of each component of the drug, since the contents and concentrations of each component vary widely among batches they must wait for either the completion of the toxicology report to begin treatment or wait for the effects of each drugs overdose to manifest. The acetaminophen content of the drug induces severe, irreversible damage to the liver when taken in high doses for long periods of time.

Sources: en.wikipedia.org

Notes from published material

Although occupational exposure to cadmium is linked to lung and prostate cancer, there is still uncertainty about the carcinogenicity of cadmium in low environmental exposure. Recent data from epidemiological studies suggest that intake of cadmium through diet is associated with a higher risk of endometrial, breast, and prostate cancer as well as with osteoporosis in humans. A recent study has demonstrated that endometrial tissue is characterized by higher levels of cadmium in current and former smoking females. Cadmium exposure is associated with a large number of illnesses including kidney disease, early atherosclerosis, hypertension, and cardiovascular diseases. Although studies show a significant correlation between cadmium exposure and occurrence of disease in human populations, a molecular mechanism has not yet been identified. One hypothesis holds that cadmium is an endocrine disruptor and some experimental studies have shown that it can interact with different hormonal signaling pathways. For example, cadmium can bind to the estrogen receptor alpha, and affect signal transduction along the estrogen and MAPK signaling pathways at low doses. The tobacco plant absorbs and accumulates heavy metals such as cadmium from the surrounding soil into its leaves. Following tobacco smoke inhalation, these are readily absorbed into the body of users. Tobacco smoking is the most important single source of cadmium exposure in the general population. An estimated 10% of the cadmium content of a cigarette is inhaled through smoking.

Eliezer Masliah (born 1958 or 1959) is a neuropathologist who was the director of the division of neuroscience at the National Institute on Aging from 2016 to 2024. In September 2024, an investigation exposed image manipulation across 132 of Masliah's research papers, raising concerns about data integrity in studies influencing Alzheimer's and Parkinson's disease treatments, pharmaceutical patents, and clinical trials. As of December 2025 he has 18 retractions.

In May 2025, the Italian Ministry of Health ordered the retail chain ODStore to recall Java Monster Vanilla and Java Monster Mocha, because their caffeine content (300 mg per can) was not in compliance with the legal limits.

John D. Rockefeller, 3rd, 1906-1978, About the Rockefellers, Rockefeller Archive Center John D Rockefeller 3rd papers, 1905-1980, DIMES: The Online Collection and Catalog of Rockefeller Archive Center. Rockefeller Brothers Fund website FBI Records: The Vault – John D. Rockefeller III at fbi.gov Asia Society – founded by Rockefeller.

== External links == Mercaptans (or Thiols) at The Periodic Table of Videos (University of Nottingham) Applications, Properties, and Synthesis of ω-Functionalized n-Alkanethiols and Disulfides – the Building Blocks of Self-Assembled Monolayers by D. Witt, R. Klajn, P. Barski, B.A. Grzybowski at Northwestern University. Mercaptan, by The Columbia Electronic Encyclopedia What is Mercaptan? Archived 2008-12-20 at the Wayback Machine, by Columbia Gas of Pennsylvania and Maryland. What Is the Worst Smelling Chemical? Archived 2011-06-06 at the Wayback Machine, by About Chemistry.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 measured?

Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.

How should SR9009 be stored?

Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.

What purity methods are used?

High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

Network